Healthcare provider profile · identity verified

John Michael Lamancuso, MD, FACP

Internal Medicine · JAMESTOWN, NY · NPI 1861436719

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	995	279
Losartan Potassium	Losartan Potassium	827	231
Amlodipine Besylate	Amlodipine Besylate	727	202
Metoprolol Succinate	Metoprolol Succinate	654	177
Atorvastatin Calcium	Atorvastatin Calcium	637	180
Pantoprazole Sodium	Pantoprazole Sodium	515	151
Omeprazole	Omeprazole	457	129
Levothyroxine Sodium	Levothyroxine Sodium	354	99
Sertraline Hcl	Sertraline Hcl	273	74
Potassium Chloride	Potassium Chloride	262	77
Famotidine	Famotidine	232	69
Hydrochlorothiazide	Hydrochlorothiazide	232	73
Valsartan	Valsartan	211	59
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	205	24
Metformin Hcl	Metformin Hcl	204	59
Celecoxib	Celecoxib	201	55
Chlorthalidone	Chlorthalidone	196	56
Tamsulosin Hcl	Tamsulosin Hcl	184	54
Citalopram Hbr	Citalopram Hydrobromide	179	45
Meloxicam	Meloxicam	173	46
Simvastatin	Simvastatin	172	47
Clopidogrel	Clopidogrel Bisulfate	170	50
Gabapentin	Gabapentin	168	50
Allopurinol	Allopurinol	163	46
Metoprolol Tartrate	Metoprolol Tartrate	157	46
Zolpidem Tartrate	Zolpidem Tartrate	156	30
Ozempic	Semaglutide	146	27
Atenolol	Atenolol	145	36
Bumetanide	Bumetanide	134	40
Fluticasone Propionate	Fluticasone Propionate	133	39
Prednisone	Prednisone	129	57
Pravastatin Sodium	Pravastatin Sodium	128	38
Tramadol Hcl	Tramadol Hcl	127	33
Eliquis	Apixaban	120	33
Felodipine Er	Felodipine	118	31
Trazodone Hcl	Trazodone Hcl	118	33
Metformin Hcl Er	Metformin Hcl	110	30
Spironolactone	Spironolactone	99	30
Glimepiride	Glimepiride	98	31
Mirtazapine	Mirtazapine	98	26
Irbesartan	Irbesartan	96	27
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	95	27
Venlafaxine Hcl Er	Venlafaxine Hcl	93	24
Carvedilol	Carvedilol	91	23
Furosemide	Furosemide	91	29
Lorazepam	Lorazepam	91	20
Lisinopril	Lisinopril	89	30
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	88	23
Paroxetine Hcl	Paroxetine Hcl	80	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	78	22
Ibandronate Sodium	Ibandronate Sodium	76	21
Clonazepam	Clonazepam	74	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	73	24
Diazepam	Diazepam	70	16
Doxycycline Monohydrate	Doxycycline Monohydrate	70	62
Alprazolam	Alprazolam	67	18
Synthroid	Levothyroxine Sodium	67	20
Ezetimibe	Ezetimibe	66	18
Donepezil Hcl	Donepezil Hcl	63	15
Pioglitazone Hcl	Pioglitazone Hcl	63	19
Duloxetine Hcl	Duloxetine Hcl	62	16
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	62	18
Escitalopram Oxalate	Escitalopram Oxalate	60	18
Xarelto	Rivaroxaban	60	15
Oxycodone Hcl	Oxycodone Hcl	59	12
Memantine Hcl	Memantine Hcl	58	12
Pregabalin	Pregabalin	58	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	57	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	52	15
Jardiance	Empagliflozin	52	16
Risperidone	Risperidone	51	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	49	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	19
Montelukast Sodium	Montelukast Sodium	49	14
Bupropion Hcl Sr	Bupropion Hcl	45	suppressed
Lansoprazole	Lansoprazole	45	12
Telmisartan	Telmisartan	45	14
Methotrexate	Methotrexate Sodium	43	suppressed
Amoxicillin	Amoxicillin	41	25
Clonidine Hcl	Clonidine Hcl	41	12
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	40	26
Ipratropium Bromide	Ipratropium Bromide	40	11
Quetiapine Fumarate	Quetiapine Fumarate	38	suppressed
Finasteride	Finasteride	37	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	36	suppressed
Folic Acid	Folic Acid	36	12
Fosinopril Sodium	Fosinopril Sodium	35	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	suppressed
Cephalexin	Cephalexin	32	20
Labetalol Hcl	Labetalol Hcl	32	suppressed
Warfarin Sodium	Warfarin Sodium	32	suppressed
Azelastine Hcl	Azelastine Hcl	31	12
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	31	suppressed
Ciclopirox	Ciclopirox Olamine	31	15
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	29	suppressed
Azithromycin	Azithromycin	28	25
Levetiracetam	Levetiracetam	26	suppressed
Nitroglycerin	Nitroglycerin	26	20
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	25	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	14
Colestipol Hcl	Colestipol Hcl	23	suppressed
Dilt-Xr	Diltiazem Hcl	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	15
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Topiramate	Topiramate	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	20	suppressed
Hydrocortisone	Hydrocortisone	20	suppressed
Lagevrio (Eua)	Molnupiravir	20	19
Metronidazole	Metronidazole	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	12
Methocarbamol	Methocarbamol	19	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	19	suppressed
Repatha Sureclick	Evolocumab	19	suppressed
Flecainide Acetate	Flecainide Acetate	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Creon	Lipase/Protease/Amylase	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Levofloxacin	Levofloxacin	16	11
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Calcitonin-Salmon	Calcitonin,salmon,synthetic	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Nystatin	Nystatin	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Methylprednisolone	Methylprednisolone	14	12
Buspirone Hcl	Buspirone Hcl	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Nadolol	Nadolol	13	suppressed
Ramipril	Ramipril	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Novofine 32	Pen Needle, Diabetic	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Cefuroxime	Cefuroxime Axetil	11	11
Divalproex Sodium	Divalproex Sodium	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed
Xtampza Er	Oxycodone Myristate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error